Cell Therapeutics Appoints Karen Ignagni to Board of Directors

        Cell Therapeutics Appoints Karen Ignagni to Board of Directors

PR Newswire

SEATTLE, Feb. 3, 2014

SEATTLE, Feb. 3, 2014 /PRNewswire/ --Cell Therapeutics, Inc. (CTI) (NASDAQ
and MTA: CTIC) today announced that Karen Ignagni has been appointed a
Director of CTI, effective immediately.Ms. Ignagni currently serves as
President and Chief Executive Officer of America's Health Insurance Plans
(AHIP), which is the trade association representing U.S. health plans, serving
members that provide healthcare, long-term care, dental and disability
benefits to more than 200 million Americans.

"We are delighted to welcome Karen Ignagni to the Board of CTI," said James A.
Bianco, M.D., President and CEO of CTI. "Karen's leadership, deep insight and
extensive health policy experience will be invaluable to CTI as we continue to
evolve as a development and commercial biopharmaceutical company."

Since joining the organization in 1993, Ms. Ignagni has won many accolades for
her leadership. AHIP was formed in late 2003 as a result of a merger of the
American Association of Health Plans (AAHP) and Health Insurance Association
of America (HIAA). Previously, she directed the AFL-CIO's Department of
Employee Benefits. In the 1980's, she was a professional staff member on the
U.S. Senate Labor and Human Resources Committee, preceded by work at the U.S.
Department of Health and Human Services. Ms. Ignagni has authored more than 90
articles on a wide range of health care policy issues, and appears regularly
before congressional committees and on national newscasts. She has served on
numerous boards and advisory groups, including presently the Board of the
National Quality Forum, the National Advisory Committee for Altarum
Institute's Center for Sustainable Health Spending and the Healthcare
Financial Management Association's Leadership Council.

"I am pleased to join CTI's board of directors at this important point when
the company has exciting late-stage clinical development programs underway and
a clear vision to improve the effectiveness and lessen the burden of patients'
cancer treatment," said Ms. Ignagni. "I look forward to working with
management and the board and contributing to the future direction of the
company."

About Cell Therapeutics, Inc.

CTI (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the
development and commercialization of an integrated portfolio of oncology
products aimed at making cancer more treatable. CTI is headquartered in
Seattle, WA. For additional information and to sign up for email alerts and
get RSS feeds, please visit www.CellTherapeutics.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of
the Safe Harbor provisions of the Private Securities Litigation Reform Act of
1995. Such statements are subject to a number of risks and uncertainties, the
outcome of which could materially and/or adversely affect actual future
results and the trading price of CTI's securities. Such statements include,
but are not limited to, statements regarding CTI's expectations with respect
to the development of CTI and its product and product candidate portfolio and
any current or potential collaborations or partnerships. Risks that contribute
to the uncertain nature of the forward-looking statements include, among
others, risks associated with the biopharmaceutical industry in general and
with CTI and its product and product candidate portfolio in particular
including, among others, risks associated with the following: that CTI cannot
predict or guarantee the pace or geography of enrollment of its clinical
trials, that CTI cannot predict or guarantee the outcome of preclinical and
clinical studies, that the second Phase 3 clinical trial of pacritinib will
not occur as planned, that CTI may not obtain favorable determinations by
other regulatory, patent and administrative governmental authorities, that CTI
may experience delays in the commencement of preclinical and clinical studies,
risks related to the costs of developing pacritinib and CTI's other product
candidates, and other risks, including, without limitation, competitive
factors, technological developments, that CTI's operating expenses continue to
exceed its net revenues, that CTI may not be able to sustain its current cost
controls or further reduce its operating expenses, that CTI may not achieve
previously announced goals and objectives as or when projected, that CTI's
average net operating burn rate may increase, that CTI will continue to need
to raise capital to fund its operating expenses, but may not be able to raise
sufficient amounts to fund its continued operation as well as other risks
listed or described from time to time in CTI's most recent filings with the
Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K. Except as
required by law, CTI does not intend to update any of the statements in this
press release upon further developments.

Contacts:
Monique Greer
+1 206-272-4343
mgreer@ctiseattle.com

Ed Bell
+1 206-282-7100
ebell@ctiseattle.com

In Europe:

CTI Life Sciences Limited, Milan Branch
Laura Villa
+39 02 89659706
lvilla@cti-lifesciences.com
CTI_EUInvestors@CTI-Lifesciences.com

SOURCE Cell Therapeutics, Inc.

Website: http://www.celltherapeutics.com
 
Press spacebar to pause and continue. Press esc to stop.